Suchergebnisse - "Sarilumab"

PubPharm (143)

91

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response

enthalten in: Journal for immunotherapy of cancer | 2020

von Arnaldez, F. | O'Day, S. | Drake, C. | +8

92

Treatment of SARS-CoV-2 : How far have we reached?

enthalten in: Drug discoveries & therapeutics | 2020

von Ahsan, W. | Javed, S. | Bratty, M. | +2

93

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

enthalten in: Arthritis research & therapy | 2020

von Gabay, C. | Burmester, G. | Strand, V. | +8

94

Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis : A Japan phase 3 trial (HARUKA)

enthalten in: Modern rheumatology | 2020

von Kameda, H. | Wada, K. | Takahashi, Y. | +4

95

Long-term safety of sarilumab in rheumatoid arthritis : an integrated analysis with up to 7 years' follow-up

enthalten in: Rheumatology (Oxford, England) | 2020

von Fleischmann, R. | Genovese, M. | Lin, Y. | +8

96

Cytokine Storm in COVID-19 : "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in"

enthalten in: Frontiers in immunology | 2020

von Castelli, V. | Cimini, A. | Ferri, C.

97

Infection by Mycobacterium chelonae at the site of administration of sarilumab for rheumatoid arthritis

enthalten in: Rheumatology (Oxford, England) | 2020

von Dos Santos Sobrín, R. | Pérez Gómez, N. | Vilas, A. | +4

98

Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis

enthalten in: Clinical pharmacokinetics | 2019

von Xu, C. | Su, Y. | Paccaly, A. | +1

99

Il-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of Il-6 inhibitor sarilumab

enthalten in: Pharmacological research | 2019

von Atzeni, F. | Nucera, V. | Masala, I. | +2

100

Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

enthalten in: Journal of managed care & specialty pharmacy | 2019

von Muszbek, N. | Proudfoot, C. | Fournier, M. | +5